Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.

Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia. Mol Cancer Ther. 2016 Jan; 15(1):94-105.

View in: PubMed

subject areas

Animals
Antineoplastic Agents
Apoptosis
Cell Cycle Checkpoints
Cell Line, Tumor
Cell Proliferation
Cyclin D2
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase Inhibitor p16
Disease Models, Animal
Dose-Response Relationship, Drug
Fusion Proteins, bcr-abl
Humans
Mice
Mutation
Piperazines
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Protein Kinase Inhibitors
Pyridines
Xenograft Model Antitumor Assays

authors with profiles

Atsushi Nemoto